• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    Arena Pharmaceuticals, Inc. (ARNA)

    2.15 Up 0.02(0.94%) Nov 27, 1:00PM EST
    ProfileGet Profile for:
    Arena Pharmaceuticals, Inc.
    6154 Nancy Ridge Drive
    San Diego, CA 92121
    United States - Map
    Phone: 858-453-7200
    Fax: 858-453-7210
    Website: http://www.arenapharm.com

    Index Membership:N/A
    Full Time Employees:229

    Business Summary 

    Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company’s products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Arena Pharmaceuticals, Inc.

    Corporate Governance 
    Arena Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Harry F. Hixson Jr., Ph.D., 76
    Chief Exec. Officer, Independent Director, Chairman of Science Committee and Member of Corp. Governance and Nominating Committee
    Dr. Dominic P. Behan Ph.D., D.Sc., 51
    Co-Founder, Chief Scientific Officer, Exec. VP, Director and Member of Science Committee
    Mr. Steven W. Spector J.D., 50
    Exec. VP, Gen. Counsel and Sec.
    Dr. William R. Shanahan Jr., M.D., J.D., 66
    Chief Medical Officer and Sr. VP
    Mr. Craig Michael Audet Ph.D., 51
    Head of Global Regulatory Affairs and Sr. VP of Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders